Today: 28 January 2026
Subscribe
Browse Category

Cancer Research News 13 January 2026 - 25 January 2026

ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

New York, Jan 25, 2026, 05:38 EST — Market closed ImmunityBio, Inc. (IBRX) shares closed Friday down 12.1% at $6.45, having traded as high as $7.88 and as low as $6.43 amid heavy volume. (Yahoo Finance) This move is significant since the stock’s been riding momentum, but Friday’s pullback hands control back to next week’s data releases. Monday’s open will…
25 January 2026
·······
Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM

Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM

New York, Jan 23, 2026, 15:38 EST — Regular session Gilead Sciences shares climbed $4.59, or 3.5%, to $135.73 in Friday afternoon trading, building on a strong two-day surge and hitting new highs. The stock started the day at $131.26 and fluctuated between $130.65 and $136.26, with roughly 8.8 million shares traded. This week, Gilead updated investors after The New…
23 January 2026
·······
ImmunityBio stock price swings as new glioblastoma data hits; IBRX traders eye Jan. 31 update

ImmunityBio stock price swings as new glioblastoma data hits; IBRX traders eye Jan. 31 update

New York, January 23, 2026, 11:18 EST — Regular session underway ImmunityBio shares jumped 2.7% to $7.54 in late morning trading Friday following new data on a chemo-free treatment for recurrent glioblastoma, a tough brain cancer. The stock fluctuated between $6.97 and $7.86, with over 31 million shares changing hands. Meanwhile, the SPDR S&P Biotech ETF slipped roughly 1.1%. ImmunityBio’s…
23 January 2026
·····
Moderna stock (MRNA) steadies in premarket after 16% surge on Merck cancer-vaccine data

Moderna stock (MRNA) steadies in premarket after 16% surge on Merck cancer-vaccine data

New York, Jan 22, 2026, 04:51 EST — Premarket. Moderna shares were flat at $49.81 in premarket trading on Thursday, after the stock jumped 15.8% in the previous session. (Yahoo Finance) The rally followed fresh five-year follow-up data on Moderna’s experimental personalised cancer vaccine used with Merck’s blockbuster immunotherapy Keytruda in high-risk melanoma, the companies said. (Merck) The move matters…
22 January 2026
······
Eli Lilly stock rises as FDA gives ‘Breakthrough’ tag to ovarian cancer drug, earnings date set

Eli Lilly stock rises as FDA gives ‘Breakthrough’ tag to ovarian cancer drug, earnings date set

New York, January 21, 2026, 17:20 EST — After-hours Eli Lilly’s stock jumped 3.6% on Wednesday, finishing at $1,078.52. The boost came after the company announced that the U.S. Food and Drug Administration awarded Breakthrough Therapy designation to its experimental ovarian cancer drug. (Stock Titan) The Breakthrough Therapy program aims to fast-track the development and review of drugs for serious…
21 January 2026
·····
ImmunityBio (IBRX) stock slips premarket after FDA maps fresh ANKTIVA resubmission route in bladder cancer

ImmunityBio (IBRX) stock slips premarket after FDA maps fresh ANKTIVA resubmission route in bladder cancer

New York, January 21, 2026, 08:47 EST — Premarket ImmunityBio’s stock dropped 5.9% to $6.10 in premarket trading Wednesday. The move followed the company’s announcement of a meeting with the U.S. Food and Drug Administration to discuss a possible resubmission of its bladder-cancer treatment, ANKTIVA. (MarketScreener) This move is significant because the FDA rejected ImmunityBio’s application last year to expand…
21 January 2026
·····
Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead

Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead

New York, Jan 20, 2026, 20:41 EST — Market closed. Merck & Co’s stock ended Tuesday 0.57% higher, closing at $109.45, supported by long-term data on a personalized melanoma vaccine it’s working on with Moderna, which helped steady investor sentiment as the session wrapped up. (Finviz) The update is crucial as Merck aims to expand its growth story beyond Keytruda,…
21 January 2026
·······
Eli Lilly stock ticks up after FDA “breakthrough” tag for ovarian cancer drug

Eli Lilly stock ticks up after FDA “breakthrough” tag for ovarian cancer drug

New York, Jan 20, 2026, 6:50 PM EST — After-hours Eli Lilly’s shares edged up 0.3% to close Tuesday at $1,041.29, then ticked 0.04% higher in after-hours action. The move followed news that the U.S. FDA granted Breakthrough Therapy designation to its ovarian cancer drug candidate, sofetabart mipitecan. (MarketScreener) The change is slight, but it hits home as investors keep…
21 January 2026
·····
ImmunityBio stock jumps 35% as ANKTIVA bladder cancer trial update puts FDA filing in view

ImmunityBio stock jumps 35% as ANKTIVA bladder cancer trial update puts FDA filing in view

New York, Jan 16, 2026, 12:51 PM EST — Regular session ImmunityBio (IBRX.O) shares jumped about 35% on Friday after the cancer drugmaker reported faster enrollment and stronger interim results in a key bladder cancer study for its ANKTIVA therapy. The stock was up $1.39 at $5.34 by 12:51 p.m. EST after hitting $5.53, with about 133 million shares traded.…
16 January 2026
·····
Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

New York, Jan 16, 2026, 10:16 EST — Regular session ImmunityBio shares surged roughly 16.5% to $4.60 Friday morning, building on a strong rally after the biotech reported better-than-expected sales momentum for its main cancer drug. The company also detailed plans for a label-expansion effort. Trading volume exceeded 56 million shares, with the stock reaching an intraday peak of $5.20.…
16 January 2026
·····
GSK stock ticks up after Summit cancer-trial tie-up — what investors watch next

GSK stock ticks up after Summit cancer-trial tie-up — what investors watch next

London, Jan 14, 2026, 09:03 GMT — Regular session GSK shares rose in early London trade on Wednesday after Summit Therapeutics said it struck a clinical trial collaboration with the British drugmaker to test a new cancer combination. (MarketScreener) The move lands as investors look for signposts on how much growth GSK can squeeze from its oncology pipeline before it…
14 January 2026
······
ImmunityBio stock pops on ANKTIVA lung cancer data; what IBRX investors watch next

ImmunityBio stock pops on ANKTIVA lung cancer data; what IBRX investors watch next

New York, Jan 13, 2026, 10:45 (EST) — Regular session ImmunityBio, Inc. shares rose about 6% on Tuesday after the company released new lung cancer trial results tied to its immune-boosting drug ANKTIVA. The stock was up 6.4% at $2.76, after touching $2.85 earlier in the session. The move matters because ImmunityBio is trying to widen the case for ANKTIVA…
13 January 2026
·····
1 2 3 … 5

Stock Market Today

  • SBM Offshore Nears Completion of EUR141 Million Share Buyback Program
    January 28, 2026, 2:06 PM EST. SBM Offshore disclosed details of its ongoing EUR141 million (approximately USD150 million) share repurchase initiative as of January 28, 2026. The program, started on April 24, 2025, aims to reduce share capital and support employee programs. As of the latest update, the company has completed 90.69% of the buyback, spending around EUR128 million to repurchase 5.75 million shares at an average price of EUR22.28 each. In the last five trading days alone, SBM acquired 98,383 shares at an average price of EUR30.61, spending just over EUR3 million. Purchases were executed via Euronext Amsterdam, CBOE DXE, and Turquoise exchanges. SBM Offshore is a leader in deepwater ocean infrastructure, focusing on cleaner energy and the blue economy.
Go toTop